How Paxlovid Approval May Influence China's Pandemic Policies
New Focus on Treatments Not Vaccines?
Executive Summary
In a surprise move, China has conditionally approved Pfizer’s oral COVID-19 antiviral Paxlovid, a development that may have far-reaching consequences for the country's pandemic policies and domestic drug developers.
You may also be interested in...
China's 'Two Sessions': Vaccines, Drugs Seen Key To Easing Restrictions Amid New Spike
The latest policies from Beijing show that the Chinese government is readying its own new vaccines and drugs for COVID-19 in a bid to gradually ease some of the strictest pandemic restrictions globally, but progress is mixed and domestic reported infections are surging to their highest level since March 2020.
CEO Podcast: Hengrui's US Subsidiary's CEO, CMO On Chinese Pharma Going Global
While many pharma firms in China choose to partner with US companies, Jiangsu Hengrui is relying on itself to go global. The Chinese pharma giant is betting on its newly established US subsidiary Luzsana in a major move to make its wide-ranging products more available, accessible and affordable to patients in the US and the rest of the world.
China's mRNA Shot Shows Benefits Over Older COVID Vaccines
Home-grown Chinese mRNA COVID-19 vaccines are more effective than domestic inactivated virus-based shots, new trial results show.